Related Experiment Video

Updated: Mar 7, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis

Siew Lian Leong1,2, Nathorn Chaiyakunapruk1,3,4,5, Shaun Wen Huey Lee6

  • 1School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, 46150, Selangor, Malaysia.

Scientific Reports
|February 25, 2017
PubMed

Insights

Certain genetic markers, including ABCC2 rs8187710, CYBA rs4673, and RAC2 rs13058338, are linked to increased risk of anthracycline-induced cardiotoxicity (ACT) in cancer patients. Further research is needed to clarify the role of pharmacogenomic screening for ACT prediction.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Cardiology

Background:

  • Anthracyclines are vital cancer treatments, but anthracycline-induced cardiotoxicity (ACT) is a major clinical challenge.
  • Identifying patients at higher risk for ACT is crucial for effective cancer management.
  • Genetic variations are increasingly explored as potential predictors of ACT.

Purpose of the Study:

  • To systematically review and assess the association between genomic markers and anthracycline-induced cardiotoxicity (ACT).
  • To identify specific genetic variants that may increase the risk of developing ACT.

Main Methods:

  • A comprehensive literature search was conducted across multiple databases (Medline, PubMed, etc.) up to May 2016.
  • Twenty-eight studies investigating genetic variants and ACT were identified and analyzed.
  • Meta-analyses were performed on 147 single nucleotide polymorphisms across 84 genes.

Main Results:

  • Three specific genetic variants were found to significantly increase the risk of ACT: ABCC2 rs8187710 (OR 2.20), CYBA rs4673 (OR 1.55), and RAC2 rs13058338 (OR 1.79).
  • The identified variants provide potential biomarkers for ACT risk assessment.

Conclusions:

  • The findings highlight specific genetic markers associated with increased ACT risk.
  • Current evidence is insufficient to establish the routine use of pharmacogenomic screening for ACT prediction before anthracycline therapy.
  • Further research is essential to validate these findings and improve diagnostic and prognostic tools for ACT.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K